Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Iqvia (IQV) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDiagnostics & ResearchIQV

Closing price · Nov 19, 2026 $251.69 -2.4% on the day · +15.7% over 12 months 52-week range $156.66 – $279.36
Get IQV alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling6last 12 months
Reported sales$39.3M0 of 18 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 26, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Eric Sherbet, See Remarks sold 4,446 shares at $278.83 ($1.2M).

Trade date
Nov 9, 2026
Disclosed to the SEC
Nov 12, 2026
Type
Sale (code S)

Read the original SEC filing ↗All IQV insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

IQV insider transactions (Form 4)

Open-market purchases and sales. 41 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 12SEC Eric SherbetSee Remarks Sell 4,44624,989 held (−15%) $278.83 $1.2M -9.7% —
Sep 4SEC James G. BerkshireSee Remarks Sell 2,66810,890 held (−20%) $261.33 $697K -3.7% —
Aug 4SEC W. Richard StaubSee Remarks Sell 5,50013,312 held (−29%) $232.68 $1.3M +8.2% —
Aug 4SEC Bhavik PatelSee Remarks Sell 1,8551,348 held (−58%) $235.27 $436K +7.0% —
Jul 31SEC Ari BousbibSee Remarks Sell 53,191885,868 held (−6%) $244.78 $13.0M +2.8% —
Jul 31SEC Ari BousbibSee Remarks Sell 44,039939,059 held (−4%) $246.08 $10.8M +2.3% —
Jul 31SEC Eric SherbetSee Remarks Sell 5,00020,999 held (−19%) $249.16 $1.2M +1.0% —
Jul 31SEC Ari BousbibSee Remarks Sell 4,584983,098 held (−0%) $246.85 $1.1M +2.0% —
Jul 31SEC Ari BousbibSee Remarks Sell 4,465987,682 held (−0%) $247.10 $1.1M +1.9% —
Jul 31SEC Keriann CherofskySee Remarks Sell 5582,989 held (−16%) $245.21 $137K +2.6% —
Dec 19SEC Ari BousbibSee Remarks Sell 36,564820,599 held (−4%) $222.43 $8.1M +13.2% —
Oct 31SEC Ari BousbibSee Remarks Sell 26,128832,171 held (−3%) $221.31 $5.8M +13.7% —
Oct 31SEC Ari BousbibSee Remarks Sell 13,741862,899 held (−2%) $219.29 $3.0M +14.8% —
Oct 31SEC Ari BousbibSee Remarks Sell 7,315876,640 held (−1%) $218.32 $1.6M +15.3% —
Oct 31SEC Ari BousbibSee Remarks Sell 4,600858,299 held (−1%) $220.11 $1.0M +14.3% —
Oct 31SEC Ari BousbibSee Remarks Sell 3,973828,198 held (−0%) $221.97 $882K +13.4% —
Oct 31SEC Eric SherbetSee Remarks Sell 4,00027,108 held (−13%) $219.70 $879K +14.6% —
Oct 31SEC Ari BousbibSee Remarks Sell 800883,955 held (−0%) $217.58 $174K +15.7% —
Historical context

Similar past setups: not applicable. IQV has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with IQV in the Research Lab

IQV has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

IQV closeInsider buyInsider sale
150200250300DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-05EEarnings release filed 2026-05-05EEarnings release filed 2026-07-28EEarnings release filed 2026-10-27Sold $436,426 on 2026-07-31 · Bhavik PatelSold $697,228 on 2026-09-02 · James G. BerkshireSold $1,239,678 on 2026-11-09 · Eric SherbetSold $1,279,740 on 2026-08-03 · W. Richard StaubSold $8,132,931 on 2025-12-18 · Ari BousbibSold $27,474,699 on 2026-07-29 · Ari Bousbib, Eric Sherbet, Keriann Cherofsky
Bought, 12 months$0
Sold, 12 months$39.3M
Insiders buying0
Insiders selling6

Iqvia insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $39.3M of IQV stock on the open market; P/E 32.2 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

IQV insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $21.5M sold (8 trades)Q4 2025Q1 2026Q2 2026Q3 2026: $29.9M sold (9 trades)Q3 2026Q4 2026: $1.2M sold (1 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$1.2M1
Q3 2026—0$29.9M9
Q2 2026—0—0
Q1 2026—0—0
Q4 2025—0$21.5M8

Valuation, profit and volume

P/E (trailing)32.2Sector median 25.0
Market value$43.57BDiagnostics & Research
Profit margin8.1%Revenue growth +8.0%
Volume vs. 50-day1.0×Last 5 sessions

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 IQVIA insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $39.3M. 0 of 18 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

IQV earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 27, 2026 +5.3% None +2.0%S&P +0.9% pending
Jul 28, 2026 +2.6% None +16.1%S&P -1.3% +5.7%
May 5, 2026 -8.8% None +9.6%S&P +2.2% +4.0%
Feb 5, 2026 -13.3% None -7.4%S&P +0.6% -6.9%
Oct 28, 2025 +9.7% None +0.2%S&P +0.3% +5.6%
Jul 22, 2025 -3.2% None +22.2%S&P +0.9% -1.6%
May 6, 2025 +5.8% None +0.7%S&P -0.4% -0.6%
Feb 6, 2025 -0.1% None +1.3%S&P -0.6% -7.9%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

IQV short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 38% of volume sold short2026-08-27: 61% of volume sold short2026-08-28: 22% of volume sold short2026-08-31: 48% of volume sold short2026-09-01: 64% of volume sold short2026-09-02: 55% of volume sold short2026-09-03: 73% of volume sold short2026-09-04: 45% of volume sold short2026-09-08: 59% of volume sold short2026-09-09: 55% of volume sold short2026-09-10: 65% of volume sold short2026-09-11: 50% of volume sold short2026-09-14: 54% of volume sold short2026-09-15: 50% of volume sold short2026-09-16: 57% of volume sold short2026-09-17: 43% of volume sold short2026-09-18: 35% of volume sold short2026-09-21: 33% of volume sold short2026-09-22: 23% of volume sold short2026-09-23: 18% of volume sold short2026-09-24: 34% of volume sold short2026-09-25: 18% of volume sold short2026-09-28: 17% of volume sold short2026-09-29: 23% of volume sold short2026-09-30: 28% of volume sold short2026-10-01: 28% of volume sold short2026-10-02: 24% of volume sold short2026-10-05: 28% of volume sold short2026-10-06: 35% of volume sold short2026-10-07: 32% of volume sold short2026-10-08: 40% of volume sold short2026-10-09: 40% of volume sold short2026-10-12: 35% of volume sold short2026-10-13: 32% of volume sold short2026-10-14: 33% of volume sold short2026-10-15: 47% of volume sold short2026-10-16: 50% of volume sold short2026-10-19: 45% of volume sold short2026-10-20: 50% of volume sold short2026-10-21: 38% of volume sold short2026-10-22: 57% of volume sold short2026-10-23: 46% of volume sold short2026-10-26: 37% of volume sold short2026-10-27: 39% of volume sold short2026-10-28: 41% of volume sold short2026-10-29: 32% of volume sold short2026-10-30: 39% of volume sold short2026-11-02: 32% of volume sold short2026-11-03: 34% of volume sold short2026-11-04: 33% of volume sold short2026-11-05: 58% of volume sold short2026-11-06: 55% of volume sold short2026-11-09: 48% of volume sold short2026-11-10: 38% of volume sold short2026-11-11: 51% of volume sold short2026-11-12: 52% of volume sold short2026-11-13: 48% of volume sold short2026-11-16: 18% of volume sold short2026-11-17: 27% of volume sold short2026-11-18: 32% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 32%20-day average: 40%Prior 2 months: 40%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded IQV

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Markwayne MullinSenate Bought $15,001 - $50,000 Dec 29, 2025Jan 16, 2026 +10.8%
John BoozmanSenate Sold $1,001 - $15,000 Oct 2, 2025Nov 15, 2025 +23.2%

Insiders at IQVIA

InsiderBoughtSoldLast filingPast buys beat S&PScore
Ari BousbibSee Remarks — $46.7M Jul 31, 2026 — —
Eric SherbetSee Remarks — $3.4M Nov 12, 2026 — —
W. Richard StaubSee Remarks — $1.3M Aug 4, 2026 — —
James G. BerkshireSee Remarks — $697K Sep 4, 2026 — —
Bhavik PatelSee Remarks — $436K Aug 4, 2026 — —
Keriann CherofskySee Remarks — $137K Jul 31, 2026 — —
Carol BurtDirector — — Apr 27, 2026 — —
John G. DanhaklDirector — — Apr 27, 2026 — —
Colleen A. GogginsDirector — — Apr 27, 2026 — —
John M. LeonardDirector — — Apr 27, 2026 — —
Michael J. FedockSee Remarks — — Feb 17, 2026 — —
Bernd HaasSee Remarks — — Feb 17, 2026 — —
Ronald E. BruehlmanSee Remarks — — Feb 10, 2026 — —
Alistair GrenfellSee Remarks — — Feb 10, 2026 — —

Board links: companies that share insiders with IQV

Directors and executives who filed Form 4s for IQV and another company in the last 12 months.

See the map →
  • LTHLife Time Group Holdings John G. Danhakl Director here · Director at LTH · latest filing Nov 13, 2026
  • NTLAIntellia Therapeutics John M. Leonard Director here · CEO, President at NTLA · latest filing Nov 3, 2026
  • RMDResMed Carol Burt Director here · Director at RMD · latest filing Nov 20, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

IQV stock: common questions

Are IQVIA insiders buying IQV stock?

No. No IQVIA insider reported an open-market purchase of IQV in the past 12 months.

Are IQVIA insiders selling IQV stock?

6 insiders reported sales worth $39.3M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is IQV's P/E ratio?

IQV trades at about 32.2 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is IQV's 52-week range?

Over the past year IQV has traded between $156.66 and $279.36. It last closed at $251.69 on Nov 19, 2026.